2031년까지 글로벌 및 페루 암 치료제 시장 전망

Global & Peru Cancer Therapeutics Market to 2031

상품코드Oman Cancer Therapeutics Market.pdf
발행기관Business Market Insights
발행일2025.05.26
페이지 수100 Pages
포맷PDF
커버리지Country

₩3,600,000 – ₩6,600,000

보고서 요약(국문)

페루는 암으로 인한 상당한 부담에 직면해 있으며, 국립보건원(INEN)은 암을 국가의 주요 사망 원인 중 하나로 지목하고 있습니다. 세계 암 통계에 따르면 2020년에는 약 69,849건의 새로운 암 발병 사례와 34,976건의 암 관련 사망 사례가 기록되었습니다. 같은 자료에 따르면 모든 연령대를 통틀어 약 4,636건의 새로운 대장암 사례가 진단되었습니다. 암 진단 건수의 증가는 화학요법, 면역요법, 표적 치료와 같은 효과적인 치료법에 대한 수요를 촉진하고 있습니다. 이러한 수요 증가는 제약 회사들이 암 환자들에게 더 나은 치료를 제공하기 위해 치료제 포트폴리오를 개발하고 확장하도록 장려하고 있습니다.

페루 정부는 암 치료 접근성을 개선하기 위해 국립종양질환연구소(INEN)를 통한 국가 암 관리 계획 시행을 포함한 여러 전략적 계획을 추진해 왔습니다. 이 계획은 조기 발견, 예방 및 포괄적인 치료를 강조합니다. 페루는 2024년 중반을 기준으로 암 환자를 위한 보편적 의료 보장 달성을 향해 지속적으로 나아가고 있습니다. MD 앤더슨 암센터와 같은 국제 기관의 지원은 매우 중요했으며, 이들 기관은 imPACT 검토단에 참여하고 현지 전문가들과 협력하여 암 예방, 진단 및 치료 전략을 강화하는 데 기여했습니다.

또한, 2023년 11월, 파마마르의 파트너사인 아디움 파마는 페루 보건부로부터 제프젤카(루르비넥테딘)의 상업화에 대한 완전한 규제 승인을 획득했습니다. 이 치료제는 백금 기반 화학요법 후 질병이 진행된 전이성 소세포폐암(SCLC) 성인 환자를 대상으로 합니다.

보고서 요약(영어 원문)

Peru faces a considerable cancer burden, with the National Institute of Health identifying cancer as one of the country's primary causes of death. According to global cancer statistics, approximately 69,849 new cancer cases and 34,976 related deaths were recorded in 2020. The same data also shows that around 4,636 new colorectal cancer cases were diagnosed across all age groups. The rising number of cancer diagnoses is driving demand for effective treatment options such as chemotherapy, immunotherapy, and targeted therapies. This growing need is encouraging pharmaceutical companies to develop and expand their therapeutic portfolios to better serve cancer patients.

To improve cancer care access, the Peruvian government has launched several strategic initiatives, including the implementation of a national cancer control plan through the Instituto Nacional de Enfermedades Neoplásicas (INEN). This plan emphasizes early detection, prevention, and comprehensive treatment. As of mid-2024, Peru continues to progress toward universal health coverage for cancer patients. International support from organizations such as the MD Anderson Cancer Center has been instrumental, with their participation in the imPACT Review mission and collaboration with local experts to enhance cancer prevention, diagnosis, and treatment strategies.

Additionally, in November 2023, Adium Pharma, a partner of PharmaMar, secured full regulatory approval from Peru’s Ministry of Health to commercialize Zepzelca (lurbinectedin). This therapy is intended for adult patients with metastatic small cell lung cancer (SCLC) who have experienced disease progression following platinum-based chemotherapy.

상세 목차

TABLE OF CONTENTS

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation:

4. Peru Cancer Therapeutics Market Landscape

4.1 Overview

4.2 Ecosystem Analysis

4.2.1 List of Vendors in the Value Chain

5. Cancer Therapeutics Market Key Market Dynamics

5.1 Cancer Therapeutics Market – Key Market Dynamics

5.2 Market Drivers

5.3 Market Restraints

5.4 Market Opportunities

5.5 Future Trends

5.6 Impact of Drivers and Restraints

6. Peru Cancer Therapeutics Market – Analysis

6.1 Peru Cancer Therapeutics Market Revenue (US$ Million), 2021–2031

6.2 Peru Cancer Therapeutics Market Revenue and Forecast Analysis

7. Peru Cancer Therapeutics Market Analysis – by Therapy Types

7.1 Peru Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types

8. Peru Cancer Therapeutics Market Analysis – by Indications

8.1 Peru Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications

9. Peru Cancer Therapeutics Market Analysis – by Distribution Channel

9.1 Peru Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel

10. Competitive Landscape

10.1 Heat Map Analysis by Key Players

10.1 Company Positioning and Concentration

11. Industry Landscape

11.1 Overview

11.2 Market Initiative

11.2 Partnerships and Collaborations

11.2 Other Developments

12. Company Profiles

12.1 Bristol-Myers Squibb Co

12.1. 1 Key Facts

12.1. 2 Business Description

12.1. 3 Products and Services

12.1. 4 Financial Overview

12.1. 5 SWOT Analysis

12.1. 6 Key Developments

12.2 AbbVie Inc

12.2. 1 Key Facts

12.2. 2 Business Description

12.2. 3 Products and Services

12.2. 4 Financial Overview

12.2. 5 SWOT Analysis

12.2. 6 Key Developments

12.3 Johnson & Johnson

12.3. 1 Key Facts

12.3. 2 Business Description

12.3. 3 Products and Services

12.3. 4 Financial Overview

12.3. 5 SWOT Analysis

12.3. 6 Key Developments

12.4 F. Hoffmann-La Roche Ltd

12.4. 1 Key Facts

12.4. 2 Business Description

12.4. 3 Products and Services

12.4. 4 Financial Overview

12.4. 5 SWOT Analysis

12.4. 6 Key Developments

12.5 Pfizer Inc

12.5. 1 Key Facts

12.5. 2 Business Description

12.5. 3 Products and Services

12.5. 4 Financial Overview

12.5. 5 SWOT Analysis

12.5. 6 Key Developments

12.6 AstraZeneca Plc

12.6. 1 Key Facts

12.6. 2 Business Description

12.6. 3 Products and Services

12.6. 4 Financial Overview

12.6. 5 SWOT Analysis

12.6. 6 Key Developments

12.7 Merck KGaA

12.7. 1 Key Facts

12.7. 2 Business Description

12.7. 3 Products and Services

12.7. 4 Financial Overview

12.7. 5 SWOT Analysis

12.7. 6 Key Developments

12.8 Novartis AG

12.8. 1 Key Facts

12.8. 2 Business Description

12.8. 3 Products and Services

12.8. 4 Financial Overview

12.8. 5 SWOT Analysis

12.8. 6 Key Developments

12.9 Astellas Pharma Inc

12.9. 1 Key Facts

12.9. 2 Business Description

12.9. 3 Products and Services

12.9. 4 Financial Overview

12.9. 5 SWOT Analysis

12.9. 6 Key Developments

12.10 Eli Lilly and Co

12.10. 1 Key Facts

12.10. 2 Business Description

12.10. 3 Products and Services

12.10. 4 Financial Overview

12.10. 5 SWOT Analysis

12.10. 6 Key Developments

13. Appendix

13.1 About Business Market Insights

13.2 List of Abbreviations

언급된 주요 기업들

TABLE OF COMPANIES

1. Bristol-Myers Squibb Co

2. AbbVie Inc

3. Johnson & Johnson

4. F. Hoffmann-La Roche Ltd

5. Pfizer Inc

6. AstraZeneca Plc

7. Merck KGaA

8. Novartis AG

9. Astellas Pharma Inc

10. Eli Lilly and Co

표 목록 (Tables)

TABLE OF TABLES

Table 1. Peru Cancer Therapeutics Market Segmentation

Table 2. List of Vendors

Table 3. Peru Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million)

Table 4. Peru Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million)

Table 5. Peru Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Therapy Types

Table 6. Peru Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Therapy Types

Table 7. Peru Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Indications

Table 8. Peru Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Indications

Table 9. Peru Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel

Table 10. Peru Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel

Table 11. List of Abbreviations

그림 목록 (Figures)

TABLE OF FIGURES

Figure 1. Impact Analysis of Drivers and Restraints

Figure 2. Peru Cancer Therapeutics Market Revenue, (US$ Million), 2021–2031

Figure 3. Heat Map Analysis by Key Players

Figure 4. Company Positioning and Concentration